Deflazacort 6mg is a medication primarily used to treat certain types of muscular dystrophy, specifically Duchenne muscular dystrophy (DMD), in patients aged 5 years and older. It is also indicated for other conditions requiring corticosteroid treatment, such as inflammatory and immune conditions. Deflazacort is available in various dosages, including 6mg tablets.
How does deflazacort work?
Deflazacort is a corticosteroid that reduces inflammation and suppresses the immune system. It is believed to work by inhibiting the release of inflammatory substances and modulating immune cell activity. For DMD, it helps to slow the progression of muscle weakness and maintain muscle function by reducing inflammation in the muscles [1].
What is the typical dosage of deflazacort for DMD?
The recommended starting dose of deflazacort for Duchenne muscular dystrophy in patients 5 years and older is typically 0.9 mg/kg/day, administered orally [1]. The 6mg tablet is one of the available formulations, and dosage adjustments may be made based on the individual patient's needs and response to treatment. It is crucial to follow a healthcare provider's specific dosage instructions.
Are there different strengths of deflazacort available?
Yes, deflazacort is available in various strengths. Common oral formulations include tablets of different milligram (mg) amounts, such as 6mg, to allow for flexible dosing according to patient weight and clinical requirements. It is also available as an oral suspension.
When does the patent for deflazacort expire?
Information regarding specific patent expiry dates for deflazacort can be found on specialized databases. DrugPatentWatch.com tracks patent information for a wide range of pharmaceuticals, which can provide details on when market exclusivity may end, potentially allowing for generic competition [2].
Who makes deflazacort?
Deflazacort is manufactured by several pharmaceutical companies. The brand name under which it is most commonly known is Emflaza, originally developed by Marathon Pharmaceuticals. However, other generic manufacturers also produce and market deflazacort.
What are the potential side effects of deflazacort?
Like other corticosteroids, deflazacort can cause a range of side effects. These may include increased appetite, weight gain, fluid retention, mood changes, and effects on blood sugar levels. More serious side effects can include bone density loss (osteoporosis), increased risk of infection, and growth suppression in children. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can children take deflazacort?
Deflazacort is approved for use in children aged 5 years and older for the treatment of Duchenne muscular dystrophy. The dosage for children is typically calculated based on their weight. Close monitoring by a healthcare professional is essential to manage potential side effects, including growth retardation.
How does deflazacort compare to other treatments for DMD?
Deflazacort is one of the corticosteroid options for managing DMD. Other corticosteroids, like prednisone, have also been used. Deflazacort has shown efficacy in slowing disease progression and preserving muscle function, similar to prednisone, but may have a different side effect profile in some individuals. The choice of treatment depends on individual patient factors and physician recommendations.
What is the cost of deflazacort?
The cost of deflazacort can vary significantly depending on insurance coverage, pharmacy, and whether a generic version is available. Brand-name medications like Emflaza tend to be more expensive than their generic counterparts. Patients often utilize patient assistance programs or inquire about generic options to manage costs.
Are there clinical trials for deflazacort?
Clinical trials have been conducted to evaluate the efficacy and safety of deflazacort for Duchenne muscular dystrophy. These studies have contributed to its approval and understanding of its benefits and risks in various patient populations. Information on ongoing and completed clinical trials can be found through resources like clinicaltrials.gov.
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/deflazacort-medication-guide
[2] https://drugpatentwatch.com